Suppr超能文献

使用化学成分确定且无动物来源的培养基生成人诱导多能干细胞源性肝芽。

Generation of human induced pluripotent stem cell-derived liver buds with chemically defined and animal origin-free media.

机构信息

Division of Regenerative Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, 108-8639, Japan.

Department of Regenerative Medicine, Yokohama City University Graduate School of Medicine, Yokohama, 236-0004, Japan.

出版信息

Sci Rep. 2020 Oct 21;10(1):17937. doi: 10.1038/s41598-020-73908-1.

Abstract

Advances in organoid technology have broadened the number of target diseases and conditions in which human induced pluripotent stem cell (iPSC)-based regenerative medicine can be applied; however, mass production of organoids and the development of chemically defined, animal origin-free (CD-AOF) media and supplements are unresolved issues that hamper the clinical applicability of these approaches. CD-AOF media and supplements ensure the quality and reproducibility of culture systems by lowering lot-to-lot variations and the risk of contamination with viruses or toxins. We previously generated liver organoids from iPSCs, namely iPSC-liver buds (iPSC-LBs), by mimicking the organogenic interactions among hepatocytes, endothelial cells (ECs), and mesenchymal cells (MCs) and recently reported the mass production of iPSC-LBs derived entirely from iPSCs (all iPSC-LBs), which should facilitate their large-scale production for the treatment of liver failure. However, in previous studies we used media originating from animals for differentiation except for the maintenance of undifferentiated iPSCs. Therefore, we developed a CD-AOF medium to generate all iPSC-LBs. We first developed a CD-AOF medium for hepatocytes, ECs, and stage-matched MCs, i.e., septum transversum mesenchyme (STM), in 2D cultures. We next generated all iPSC-LBs by incubating individual cell types in ultra-low attachment micro-dimple plates. The hepatic functions of all iPSC-LBs generated using the CD-AOF medium were equivalent to those of all iPSC-LBs generated using the conventional medium both in vitro and in vivo. Furthermore, we found that this CD-AOF medium could be used in several cell culture settings. Taken together, these results demonstrate the successful development of a CD-AOF medium suitable for all iPSC-LBs. The protocol developed in this study will facilitate the clinical applicability of all iPSC-LBs in the treatment of liver diseases.

摘要

类器官技术的进步拓宽了目标疾病和病症的范围,使得基于人诱导多能干细胞(iPSC)的再生医学可以得到应用;然而,类器官的大规模生产以及化学定义、无动物源(CD-AOF)的培养基和补充剂的开发仍然是尚未解决的问题,这些问题阻碍了这些方法的临床应用。CD-AOF 培养基和补充剂通过降低批次间的差异以及病毒或毒素污染的风险,确保了培养系统的质量和可重复性。我们之前通过模拟肝细胞、内皮细胞(EC)和间充质细胞(MC)之间的器官发生相互作用,从 iPSCs 中生成了肝类器官,即 iPSC-肝芽(iPSC-LB),并最近报道了完全由 iPSCs 衍生的 iPSC-LB 的大规模生产(所有 iPSC-LB),这应该有助于它们的大规模生产,以治疗肝衰竭。然而,在之前的研究中,我们除了维持未分化的 iPSC 之外,都使用了动物来源的培养基来进行分化。因此,我们开发了一种 CD-AOF 培养基来生成所有 iPSC-LB。我们首先在 2D 培养中开发了一种用于肝细胞、EC 和阶段匹配的 MC(即横膈膜间充质)的 CD-AOF 培养基。然后,我们通过在超低附着微凹板中孵育单个细胞类型来生成所有 iPSC-LB。使用 CD-AOF 培养基生成的所有 iPSC-LB 的肝功能在体外和体内与使用传统培养基生成的所有 iPSC-LB 相当。此外,我们发现这种 CD-AOF 培养基可以在几种细胞培养环境中使用。综上所述,这些结果证明了适合所有 iPSC-LB 的 CD-AOF 培养基的成功开发。本研究中开发的方案将促进所有 iPSC-LB 在治疗肝脏疾病中的临床应用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0ad9/7578079/dfe97aa432c6/41598_2020_73908_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验